

## Announcement

Athens, January 15<sup>th</sup> 2018

Boehringer Ingelheim and Merial have decided to join forces and continue as one Animal Health company. The new Boehringer Ingelheim has the ambition to grow into the number 1 Animal Health company in the world by becoming the partner of choice in achieving animal well-being through advanced preventive care.

In Greece, Boehringer Ingelheim / Merial portfolio was represented through two valued partners: Altavet and Gerolymatos International.

As part of the integration, Boehringer Ingelheim has decided to concentrate product portfolio as per January 1, 2018 with one partner: Gerolymatos International.

Gerolymatos International is active in the Greek veterinary market since the late 1950's and has been handling the Merial portfolio successfully since 2012. Apart from the Vet Business Unit, Gerolymatos International is also active in Optics and OTC products and exports its own products to over 55 countries worldwide.

Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Innovative medicines for people and animals – this is what the research-driven pharmaceutical company Boehringer Ingelheim has stood for over more than 130 years. Day by day, some 50,000 employees create value through innovation for the three business areas Human Pharmaceuticals, Animal Health and Biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros.

Both companies have set as a first priority the smooth supply of BI products in the Greek market and are confident that the long-lasting relationship with the Greek veterinary community will be further enhanced by this cooperation.

E. van Houten



Head of Animal Health  
Boehringer Ingelheim

D. Anagnostakis



President & Managing Director  
Boehringer Ingelheim Hellas

N. Gerolymatos



President  
Gerolymatos International

